NDLI: Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis

Content Provider	Springer Nature Link
Author	Notcutt, William G.
Copyright Year	2015
Abstract	The endocannabinoid system was discovered in 1988 but has received little attention for its potential therapeutic possibilities. That has started to change, and since 2000, a significant number of clinical trials of cannabinoids, principally for the control of spasticity in multiple sclerosis, have been undertaken. These studies have been difficult because of the nature of the disease and have involved patients for whom other therapies have failed or proved inadequate. This paper outlines the background to the use of cannabinoids available and discusses the principles of practice associated with their safe use. The focus has been on nabiximols, being the most studied and the only cannabinoid that has been both adequately researched for use in multiple sclerosis and granted a license by the regulators. However, what has emerged is that the effect for many patients can be much wider than just control of spasticity. Within and outside of neurology there seems to be an expanding range of possibilities for the therapeutic use of cannabinoids.
Starting Page	769
Ending Page	777
Page Count	9
File Format	PDF
ISSN	19337213
Journal	NeuroRX
Volume Number	12
Issue Number	4
e-ISSN	18787479
Language	English
Publisher	Springer US
Publisher Date	2015-08-20
Publisher Institution	American Society for Experimental NeuroTherapeutics
Publisher Place	New York
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Cannabinoids pain nabiximols multiple sclerosis Neurosciences Neurology Neurosurgery Neurobiology
Content Type	Text
Resource Type	Article
Subject	Neurology (clinical) Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis

Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside

Interferon-β treatment for multiple sclerosis

Remyelination Therapy for Multiple Sclerosis

Alemtuzumab Therapy for Multiple Sclerosis

Cell Therapy for Multiple Sclerosis

Remyelinating Pharmacotherapies in Multiple Sclerosis

Daclizumab Therapy for Multiple Sclerosis

The New Era of Multiple Sclerosis Therapeutics

Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis

Similar Documents

Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis

Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside

Interferon-β treatment for multiple sclerosis

Remyelination Therapy for Multiple Sclerosis

Alemtuzumab Therapy for Multiple Sclerosis

Cell Therapy for Multiple Sclerosis

Remyelinating Pharmacotherapies in Multiple Sclerosis

Daclizumab Therapy for Multiple Sclerosis

The New Era of Multiple Sclerosis Therapeutics

Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis